Evidence map›Paper›PMID 42413329›Full record

ArticleESMO open2026

Efficacy and safety of durvalumab plus gemcitabine-cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma.

C-C Hsu, K-Y Yeh, C-F Chang, C-F Wu, H-W Kou, Y-F Chen, M-Y Chen, J-T Hsu, C-N Yeh, C-E Wu and 12 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

C-C HsuDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
K-Y YehDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan.
C-F ChangDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Taoyuan, Taoyuan, Taiwan.
C-F WuDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan.
H-W KouDepartment of General Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Y-F ChenDepartment of General Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
M-Y ChenDepartment of General Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
J-T HsuDepartment of General Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
C-N YehDepartment of General Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
C-E WuDepartment of Hematology and Oncology, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.
W-K HuangDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
C-H KuDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
C-C LanDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
C-L HsiehDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Y-W HsuDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
C-H HsiehDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
L-L ChangDepartment of Nursing, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
S-C HuangDepartment of Pathology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
T-C ChenDepartment of Pathology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
J-S ChenDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Y-S HungDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
W-C ChouDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address: wenchi3992@yahoo.com.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCombined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer characterized by features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). As cHCC-CCA prognosis often falls between HCC and CCA or resembles CCA, we compared the outcomes of durvalumab plus gemcitabine-cisplatin (GCD) in patients with cHCC-CCA and CCA in a real-world setting. MATERIALS AND

methodsThis retrospective multicenter study included patients with histologically confirmed unresectable or metastatic CCA or cHCC-CCA who underwent first-line GCD at four centers in Taiwan between 2021 and 2025. Outcomes included overall survival (OS), progression-free survival (PFS), tumor response, and safety. Propensity score matching (PSM) was performed to balance baseline characteristics.

resultsAmong the 175 patients, 154 had CCA and 21 had cHCC-CCA. Before matching, patients with cHCC-CCA more frequently had elevated α-fetoprotein levels and poor biliary drainage; however, these imbalances were resolved after PSM. Before PSM, patients with CCA and cHCC-CCA had median OS of 13.3 months [95% confidence interval (CI) 9.5-17.1] and 13.8 months (95% CI 2.1-25.6, P = 0.60) and median PFS of 5.1 months (95% CI 4.7-5.5) and 5.3 months (95% CI 3.1-7.5, P = 0.40), respectively. After PSM, both OS and PFS rates were similar between the groups. The objective response rate was higher in the cHCC-CCA group (38.1% versus 23.4% before PSM, P = 0.15; 38.1% versus 23.8% after PSM, P = 0.24), whereas the disease control rates were identical (66.7% after PSM). The most common toxicities were hematologic events, with both groups demonstrating similar rates of anemia, thrombocytopenia, leukopenia, and neutropenia.

conclusionsThis study demonstrates that patients with cHCC-CCA derive comparable clinical benefit from GCD as those with CCA in terms of efficacy and safety. These findings support the incorporation of immunochemotherapy into the treatment framework for cHCC-CCA and provide a rationale for its use in clinical practice.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaCisplatinDeoxycytidineLiver NeoplasmsAgedFemaleGemcitabineHumansMaleMiddle AgedRetrospective StudiesTaiwanAntibodies, MonoclonalCisplatinDeoxycytidinedurvalumabGemcitabinecholangiocarcinomahepatocellular carcinomaimmune checkpoint inhibitormixed hepatocellular-cholangiocarcinomapropensity score matching

Identifiers

PMID42413329
PMCPMC13356709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.